- Home
- BMO vs SNY Comparison
BMO vs SNY Comparison
Compare BMO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMO | SNY |
|---|---|---|
| Founded | 1817 | 1994 |
| Country | Canada | France |
| Employees | N/A | 74846 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6B | 116.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BMO | SNY |
|---|---|---|
| Price | $139.12 | $43.88 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $163.00 | $61.50 |
| AVG Volume (30 Days) | 663.9K | ★ 4.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 3.34% | ★ 3.64% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.28 | $3.01 |
| Revenue Next Year | $4.45 | $5.80 |
| P/E Ratio | $17.46 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $85.40 | $43.51 |
| 52 Week High | $149.01 | $59.17 |
Technical Indicators
Market Signals| Indicator | BMO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 44.27 | 33.40 |
| Support Level | $136.90 | N/A |
| Resistance Level | $147.68 | $48.97 |
| Average True Range (ATR) | 3.07 | 0.68 |
| MACD | -0.86 | -0.35 |
| Stochastic Oscillator | 5.71 | 9.64 |
Price Performance
Historical ComparisonAbout BMO Bank Of Montreal
Bank of Montreal is a diversified financial-services provider based in North America with over CAD 1.4 trillion in assets. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the US.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.